March 7, 2017 | Cell Therapy

Safety First: Shipping Cell Therapy Materials

Shipping_cell_therapy_March2017.png

Cell therapies are at the forefront of saving lives – providing critical treatments to patients who might otherwise have very few viable options. Because these therapies are so unique, there are a multitude of complex challenges that must be overcome. Of particular concern is product potency. After the manufacturing process, the shipment of the final product is crucial to ensure the patient is treated with an efficacious therapy. Without a safe delivery of incoming material, the entire manufacturing process could be compromised, resulting in a lost batch or lost time, and could ultimately lead to no final product.

 

Choosing the right shipping container for your cell therapy materials

When selecting a shipping container to transport your cell therapy products, cost, reliability and ease-of-use should be considered.

First and foremost, the shipping container should be equipped with features that will help ensure the safety of your product. Given that most incoming products need to be shipped at a specific temperature, it’s important that a temperature tracking device is used; it’s a simple way to see if the product was maintained in an acceptable temperature range. In addition, it must be able to withstand environmental changes, orientations, throwing, banging and dropping that occur daily.

Testing is also crucial for ensuring the right container is chosen. While some cold chain logistic companies supply their own validation data, we generally recommend customers test the container with their own product in expected shipping conditions to ensure the cells are still viable and potent upon getting to their destination. In addition, customers can send the shipment to an independent testing facility, which will challenge the shipping container by running summer/winter temperature profiles.

 

It’s not just about the container….

While choosing the right container is important, it is also critical to select the appropriate shipping service. Smaller courier companies with specific cell therapy experience are generally preferable to large shipping companies. Given that these are critical, life-saving products, we often recommend using a specialized courier to minimize risk.

 

Smart shipping: the new kid on the block

More recently, there have been new, innovative shipping developments that provide users with more traceability of their cell therapy products. “Smart shippers” have GPS, as well as a variety of sensors for temperature, pressure, orientation, humidity, and light. Light sensors can indicate if the shipping container has been opened prematurely. GPS is especially useful for alerting the manufacturing facility or clinical site that the product is nearby so that preparation can begin, thus improving logistics.

While smart shippers are a great idea, for now they appear to be more suited for customers who are in Phase 3 or commercial stages—those with the higher product volumes needed to justify the cost of these shippers. The justification of using an expensive smart shipper may also depend on the product and the disease it is intended to treat, in the case of rare or difficult-to-treat ailments.

PCT has extensive experience evaluating and validating shipping containers. Often, one vital part of the shipping chain in cell therapies is cryopreservation. Click the button below to download a complementary white paper exploring the topic of cryopreservation.

Download White Paper

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH are all now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

Stay up to date on the latest cell therapy industry insights

Related Articles

February 16, 2017

Challenges and Optimization of Apheresis Collection

On Thursday, February 23 from 2:00 – 3:30 PM EST, Sanjin Zvonic, PhD, PCT’s Senior Director, Business Leader, Clinical Cell Therapy Manufacturing, will be speaking as part of a panel on a ...

Read More
April 18, 2017

Impact of Apheresis Collection Quality on Manufacturing of Cell Therapeutics

One of the most critical first steps in the development of many cell therapies is having optimized apheresis collections. Starting with variable or low-quality apheresis presents a ...

Read More
April 25, 2017

Planning Ahead: Selecting Appropriate Source Materials for Cell-Based Therapy Manufacturing

Cell-based therapies are rapidly changing the way the medical industry is treating a wide range of diseases. As the development of these therapies continues to advance, effective planning ...

Read More